Navigation Links
Failure of 'scout cells' may lead to cancer in transplant patients

A serious form of cancer that occurs in some transplant patients may arise because cells that normally serve as scouts for the immune system become weakened, a new study suggests.

The cancer is caused by Epstein-Barr virus (EBV), a herpesvirus that infects more than 90 percent of Americans but is ordinarily kept under control by the immune system. That control can be lost in people whose immune system is suppressed to prevent rejection of a transplanted organ.

The cancer, called post-transplant lymphoproliferative disorder (PTLD), arises only in some transplant patients, but doctors don't know why.

This study, led by Ohio State University scientists, begins to answer that question.

The findings are published in the August issue of the American Journal of Transplantation.

We've identified a mechanism that may explain why some patients develop PTLD and others don't, says study leader Anne M. VanBuskirk, assistant professor of surgery and an OSU Comprehensive Cancer Center researcher.

If we can understand the mechanism, perhaps we can discover how to prevent this type of cancer in transplant patients.

The incidence of this cancer varies according to the organ transplanted, occurring in 1 to 2 percent of kidney transplant patients and in up to 20 percent of bone marrow and lung transplant patients. The disease usually arises within six months to a year after transplantation, and it can have a 70- to 80-percent mortality rate.

The study by VanBuskirk and her colleagues examines two types of immune cells: cells that act as scouts scientists call them antigen-presenting cells and memory T cells.

Scout cells detect the presence of viruses and other invaders and alert the immune system to the infection. Memory T cells are immune cells that have fought an earlier infection and remain ready to respond quickly should that infection occur again.

Most people are infected by EBV earl
'"/>

Source:Ohio State University


Page: 1 2 3

Related biology news :

1. Implanted Devices Detect High-Risk Heart Failure Patients
2. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
3. Failure to meet United Nations sanitation target could affect millions of the worlds poorest
4. Two chemicals boost immune cells ability to fight HIV without gene therapy
5. Once given no respect, cells tiny RNAS take drivers seat
6. How HIV disables the cells call for help
7. Stem cells electric abilities might help their safe clinical use
8. Scientists discover the molecular switch for nerve cells insulating jelly rolls
9. New insight into machinery of immune cells tentacles
10. Allergy cells can aggravate cancer and psoriasis
11. A key antibody, IgG, links cells capture and disposal of germs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Failure scout cells may lead cancer transplant patients

(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... at the University of Georgia have discovered a central ... The misregulation of this switch may play a role ... the aggressiveness of tumors themselves. "Malignant cancer arises ... from their primary tissue location," said Natalia Starostina assistant ...
... BOSTON (December 7, 2010) Newly-created bioactive peptides promote ... and epithelial tissue, such as skin. These wound-healing peptides, ... in Wound Healing Research, increased angiogenesis in vitro by ... print this week in Wound Repair and Regeneration ...
... will meet again in So Paulo at the international ... to monitor new biodiversity conservation targets. The goal of ... for the conservation of biodiversity, as well as mechanisms ... event is organized by the Biota-FAPESP, the So Paulo ...
Cached Biology News:Study: mechanism that controls cell movement linked to tumors becoming more aggressive 2Study: mechanism that controls cell movement linked to tumors becoming more aggressive 3Bioactive peptides found to promote wound healing 2Bioactive peptides found to promote wound healing 3Biodiversity targets for the future 2Biodiversity targets for the future 3
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... Tunnell Consulting, Inc. today ... senior statistician and Principal, a position to which she ... management and analysis of complex and large data sets ... “We’re delighted to have Julia join the Tunnell team ... Dr. Philippe Cini, Group Vice President and leader of ...
(Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
(Date:5/20/2015)... May 20, 2015  Haemonetics Corporation (NYSE: HAE ... & CEO, will present at The Jefferies 2015 Global ... on June 1 st , 2015 at 8:30am Eastern ... Concannon,s presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... 22, 2012 Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, today ... year ended December 31, 2011: Fourth Quarter ... million, compared to the $5.3 million for the fourth quarter ...
... The new Dynaflow Resolve System was ... to meet the demand for a simpler technology capable ... an advanced automated perfusion system that enables novel experimental ... using any cell type, and any compound. The new ...
... an inVentiv Health company and the leading management ... industry, today announced the launch of Encuity Research, ... a six-year veteran with Campbell Alliance, will serve ... be based in Newtown, PA. (Photo: ...
Cached Biology Technology:Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 2Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 3Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 5Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 6Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 7Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 8Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 9Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 10Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays 2Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 2Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 3Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 4Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 5